## STROBE Statement—checklist of items that should be included in reports of observational studies

Manuscript title: The use of antibiotic-loaded bone cement and systemic antibiotic prophylactic use in 2,971,357 primary total knee arthroplasties from 2010 to 2020: an international register-based observational study among countries in Africa, Europe, North America, and Oceania

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1	•
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3	
Objectives	3	State specific objectives, including any prespecified hypotheses	3	
Methods				
Study design	4	Present key elements of study design early in the paper	4-5	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5	
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants.  Describe methods of follow-up  Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls  Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed  Case-control study—For matched studies, give matching criteria and the number of controls per case	Not applicable (NA)	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	2, 3, 5	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement).  Describe comparability of assessment methods if there is more than one group	4-5	
Bias	9	Describe any efforts to address potential sources of bias	11-12	Under the study limitation
Study size	10	Explain how the study size was arrived at	5,	& figure 1

Continued on next page

Quantitative	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which	NA	
variables		groupings were chosen and why		
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	NA	
		(b) Describe any methods used to examine subgroups and interactions	NA	
		(c) Explain how missing data were addressed		Missing values were presented
				in the tables/footnotes
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed	NA	
		Case-control study—If applicable, explain how matching of cases and controls was addressed		
		Cross-sectional study—If applicable, describe analytical methods taking account of sampling		
		strategy		
		(e) Describe any sensitivity analyses	NA	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined	5	& figure 1
		for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed		
		(b) Give reasons for non-participation at each stage	5	
		(c) Consider use of a flow diagram		Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on	7-8	& table 3, Supplement tables
		exposures and potential confounders		(1-3)
		(b) Indicate number of participants with missing data for each variable of interest		Table 3 and supplement tables
				1-3
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	7-8	Figure 2 &3
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	7-8	<i>Tables 2, 4-7, figures 2&amp;3</i>
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	NA	
		Cross-sectional study—Report numbers of outcome events or summary measures	7-8	<i>Tables 2, 4-7, figures 2&amp;3</i>
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision	NA	
		(eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were		
		included		
		(b) Report category boundaries when continuous variables were categorized	NA	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time	NA	
		period		

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA		
Discussion					
Key results	18	Summarise key results with reference to study objectives	9		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss	11-12		
		both direction and magnitude of any potential bias			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of	9-12		
		analyses, results from similar studies, and other relevant evidence			
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13		
Other information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the	5-6		
		original study on which the present article is based			

<sup>\*</sup>Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.